Human medicines European public assessment report (EPAR): Tecentriq, atezolizumab, Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma, Date of authorisation: 20/09/2017, Revision: 23,

Human medicines European public assessment report (EPAR): Tecentriq, atezolizumab, Carcinoma, Transitional Cell;Carcinoma, Non-Small-Cell Lung;Urologic Neoplasms;Breast Neoplasms;Small Cell Lung Carcinoma, Date of authorisation: 20/09/2017, Revision: 23, Status: Authorised